newsfilter
← Latest News
GlobeNewswire·

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

Submission seeks to extend the Ameluz® label beyond the face and scalp to treatment fields of up to approximately 240 cm² on the rest of the body, with an adjusted illumination protocol WOBURN, Mass., Oct. 08, 2026